Histological examination of patients who died after receiving treatment with cediranib, an inhibitor of VEGFR2 tyrosine kinases (56) or bevacizumab regimen (57) showed that the glioma cells were growing around preexisting vessels in a nonangiogenic fashion. The gene discussed is KDR; the disease is central nervous system cancer.